Carole A. Sable

7.0k total citations · 2 hit papers
47 papers, 5.1k citations indexed

About

Carole A. Sable is a scholar working on Infectious Diseases, Epidemiology and Small Animals. According to data from OpenAlex, Carole A. Sable has authored 47 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Infectious Diseases, 27 papers in Epidemiology and 6 papers in Small Animals. Recurrent topics in Carole A. Sable's work include Antifungal resistance and susceptibility (28 papers), Fungal Infections and Studies (12 papers) and Pneumocystis jirovecii pneumonia detection and treatment (8 papers). Carole A. Sable is often cited by papers focused on Antifungal resistance and susceptibility (28 papers), Fungal Infections and Studies (12 papers) and Pneumocystis jirovecii pneumonia detection and treatment (8 papers). Carole A. Sable collaborates with scholars based in United States, United Kingdom and Belgium. Carole A. Sable's co-authors include Nicholas A. Kartsonis, Robert Lupinacci, Mark J. DiNubile, Gerald R. Donowitz, Robert F. Betts, John R. Perfect, Arnaldo Lopes Colombo, Thomas J. Walsh, Coleman Rotstein and Luis Thompson-Moya and has published in prestigious journals such as New England Journal of Medicine, Blood and Cancer.

In The Last Decade

Carole A. Sable

46 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis

2002 990 citations Robert F. Betts, Coleman Rotstein et al. New England Journal of Medicine profile →
Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

2004 644 citations Thomas J. Walsh, Hedy Teppler et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carole A. Sable United States	28	3.8k	3.4k	780	566	540	47	5.1k
Coleman Rotstein Canada	39	4.2k 1.1×	3.8k 1.1×	702 0.9×	1.1k 1.9×	286 0.5×	157	6.6k
Markus Ruhnke Germany	45	5.0k 1.3×	4.4k 1.3×	603 0.8×	1.1k 1.9×	495 0.9×	151	7.0k
Stanley W. Chapman United States	33	4.1k 1.1×	3.8k 1.1×	526 0.7×	283 0.5×	737 1.4×	75	5.9k
Mindy G. Schuster United States	25	5.5k 1.4×	4.6k 1.4×	603 0.8×	861 1.5×	385 0.7×	56	6.9k
Oscar Marchetti Switzerland	39	4.5k 1.2×	3.9k 1.2×	943 1.2×	1.3k 2.3×	360 0.7×	78	6.4k
Nicholas A. Kartsonis United States	36	4.2k 1.1×	3.3k 1.0×	997 1.3×	438 0.8×	526 1.0×	63	5.5k
Jorge Garbino Switzerland	32	2.7k 0.7×	3.0k 0.9×	414 0.5×	214 0.4×	386 0.7×	75	4.9k
Nina Singh United States	54	5.9k 1.5×	8.1k 2.4×	466 0.6×	766 1.4×	473 0.9×	162	10.5k
Pranatharthi Chandrasekar United States	43	4.8k 1.2×	4.3k 1.3×	732 0.9×	1.1k 2.0×	548 1.0×	160	7.1k
Michél Laverdière Canada	34	3.3k 0.9×	2.9k 0.9×	430 0.6×	592 1.0×	392 0.7×	103	4.4k

Countries citing papers authored by Carole A. Sable

Since Specialization

Citations

This map shows the geographic impact of Carole A. Sable's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carole A. Sable with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carole A. Sable more than expected).

Fields of papers citing papers by Carole A. Sable

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carole A. Sable. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carole A. Sable. The network helps show where Carole A. Sable may publish in the future.

Co-authorship network of co-authors of Carole A. Sable

This figure shows the co-authorship network connecting the top 25 collaborators of Carole A. Sable. A scholar is included among the top collaborators of Carole A. Sable based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carole A. Sable. Carole A. Sable is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zalacaín, Magdalena, Ian Morrissey, Stephen Hawser, et al.. (2024). Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 68(3). e0112023–e0112023. 6 indexed citations

Zalacaín, Magdalena, Carole A. Sable, Marlène Murris, et al.. (2023). Higher levels of Pseudomonas aeruginosa LasB elastase expression are associated with early-stage infection in cystic fibrosis patients. Scientific Reports. 13(1). 14208–14208. 9 indexed citations

Das, Shampa, Adam Johnson, Laura McEntee, et al.. (2020). Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. 64(11). 14 indexed citations

Sable, Carole A. & W. Michael Scheld. (2015). Theoretical and Practical Considerations of Antibiotic Therapy for Bacterial Meningitis. Antibiotics and chemotherapy/Antibiotica et chemotherapia. 45. 96–117.

Balkovec, James M., David L. Hughes, Prakash Masurekar, et al.. (2013). Discovery and development of first in class antifungal caspofungin (CANCIDAS®)—A case study. Natural Product Reports. 31(1). 15–34. 122 indexed citations

Hiemenz, J., Issam Raad, J. Maertens, et al.. (2010). Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. European Journal of Clinical Microbiology & Infectious Diseases. 29(11). 1387–1394. 32 indexed citations

DiNubile, Mark J., Kim M. Strohmaier, Robert Lupinacci, et al.. (2008). Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections. European Journal of Clinical Microbiology & Infectious Diseases. 27(8). 663–670. 6 indexed citations

DiNubile, Mark J., Robert Lupinacci, Kim M. Strohmaier, Carole A. Sable, & Nicholas A. Kartsonis. (2007). Invasive candidiasis treated in the intensive care unit: Observations from a randomized clinical trial. Journal of Critical Care. 22(3). 237–244. 36 indexed citations

Petrović, Jelena, A. Ngai, Susan K. Bradshaw, et al.. (2007). Efficacy and Safety of Caspofungin in Solid Organ Transplant Recipients. Transplantation Proceedings. 39(10). 3117–3120. 15 indexed citations

10.

Pauw, B.E. de, Carole A. Sable, Thomas J. Walsh, et al.. (2006). Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transplant Infectious Disease. 8(1). 31–37. 28 indexed citations

11.

DiNubile, Mark J., Darcy A. Hille, Carole A. Sable, & Nicholas A. Kartsonis. (2005). Invasive candidiasis in cancer patients: observations from a randomized clinical trial. Journal of Infection. 50(5). 443–449. 41 indexed citations

12.

Maertens, Johan, Axel Glasmacher, Dominik Selleslag, et al.. (2005). Evaluation of Serum Sandwich Enzyme-Linked Immunosorbent Assay for Circulating Galactomannan during Caspofungin Therapy: Results from the Caspofungin Invasive Aspergillosis Study. Clinical Infectious Diseases. 41(1). e9–e14. 30 indexed citations

13.

Kartsonis, Nicholas A., Lori Mixson, Chao‐Min Hoe, et al.. (2005). Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome. Antimicrobial Agents and Chemotherapy. 49(9). 3616–3623. 110 indexed citations

14.

Maertens, J., Issam Raad, G. Petrikkos, et al.. (2004). Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. Clinical Infectious Diseases. 39(11). 1563–1571. 465 indexed citations

15.

DiNubile, Mark J., Robert Lupinacci, Rayanne S. Berman, & Carole A. Sable. (2002). Response and Relapse Rates of Candidal Esophagitis in HIV-Infected Patients Treated with Caspofungin. AIDS Research and Human Retroviruses. 18(13). 903–908. 27 indexed citations

16.

Villanueva, Álvaro, Eduardo Gotuzzo, Eduardo Arathoon, et al.. (2002). A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. The American Journal of Medicine. 113(4). 294–299. 211 indexed citations

17.

Betts, Robert F., Coleman Rotstein, Arnaldo Lopes Colombo, et al.. (2002). Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis. New England Journal of Medicine. 347(25). 2020–2029. 990 indexed citations breakdown →

18.

Sable, Carole A. & Gerald L. Mandell. (1996). The role of molecular techniques in the understanding of emerging infections. Molecular Medicine Today. 2(3). 120–128. 3 indexed citations

19.

Sable, Carole A. & Frederick G. Hayden. (1995). ORTHOMYXOVIRAL AND PARAMYXOVIRAL INFECTIONS IN TRANSPLANT PATIENTS. Infectious Disease Clinics of North America. 9(4). 987–1003. 35 indexed citations

20.

High, Kevin P., Robert G. Sawyer, Carole A. Sable, et al.. (1992). A Controlled Trial of Scheduled Replacement of Central Venous and Pulmonary-Artery Catheters. New England Journal of Medicine. 327(15). 1062–1068. 299 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact